Acrodysostosis is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multiple systems. Early identification and normalisation of the disease are essential for improving the prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of Acrodysostosis treatment programs include personalized development, usually drug therapy, rehabilitation interventions, regular follow-up, and multidimensional management. In recent years, with the development of therapeutic-focused, immune-regulatory therapies and precision medicine, many previously difficult-to-treat autoimmune and rheumatic immune disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored throughout the treatment process, and timely adjusted according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of acrodysostosis. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of autoimmunity and rheumatic immunity, to provide the following services to patients: 1.
Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2. Interviews in China: Arrangement with authoritative experts for face-to-face diagnosis, development of personalized treatment plans; 3. Full-service: One-stop services: medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: Establishment of a chronic disease management file, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.